Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.78), $0.08 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $11.51 million versus the consensus estimate of $13.84 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.